These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38702998)

  • 21. Perceptions of patient disease burden and management approaches in systemic mastocytosis: Results of the TouchStone Healthcare Provider Survey.
    Mesa RA; Sullivan EM; Dubinski D; Carroll B; Slee VM; Jennings SV; Finnerty CC; Bohannon LS; Mathias SD; Lahue BJ; Castells MC
    Cancer; 2022 Oct; 128(20):3700-3708. PubMed ID: 35996871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
    Ustun C; DeRemer DL; Akin C
    Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
    Horny HP; Sotlar K; Sperr WR; Valent P
    J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
    De Vita S; Schneider RK; Garcia M; Wood J; Gavillet M; Ebert BL; Gerbaulet A; Roers A; Levine RL; Mullally A; Williams DA
    PLoS One; 2014; 9(5):e96209. PubMed ID: 24788138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Digital PCR: A Sensitive and Precise Method for
    Greiner G; Gurbisz M; Ratzinger F; Witzeneder N; Simonitsch-Klupp I; Mitterbauer-Hohendanner G; Mayerhofer M; Müllauer L; Sperr WR; Valent P; Hoermann G
    Clin Chem; 2018 Mar; 64(3):547-555. PubMed ID: 29237714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case Report: Evolution of
    Sciumè M; Ceparano G; Eller-Vainicher C; Fabris S; Lonati S; Croci GA; Baldini L; Grifoni FI
    Front Oncol; 2021; 11():734025. PubMed ID: 34917498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avapritinib for Systemic Mastocytosis.
    Bose P; Verstovsek S
    Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.
    Fritsche-Polanz R; Fritz M; Huber A; Sotlar K; Sperr WR; Mannhalter C; Födinger M; Valent P
    Mol Oncol; 2010 Aug; 4(4):335-46. PubMed ID: 20471335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
    Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
    Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.
    Kristensen T; Vestergaard H; Møller MB
    J Mol Diagn; 2011 Mar; 13(2):180-8. PubMed ID: 21354053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced DNA methylation and hydroxymethylation in patients with systemic mastocytosis.
    Leoni C; Montagner S; Deho' L; D'Antuono R; De Matteis G; Marzano AV; Merante S; Orlandi EM; Zanotti R; Monticelli S
    Eur J Haematol; 2015 Dec; 95(6):566-75. PubMed ID: 25688802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
    Nedoszytko B; Arock M; Lyons JJ; Bachelot G; Schwartz LB; Reiter A; Jawhar M; Schwaab J; Lange M; Greiner G; Hoermann G; Niedoszytko M; Metcalfe DD; Valent P
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive mutational profiling in advanced systemic mastocytosis.
    Schwaab J; Schnittger S; Sotlar K; Walz C; Fabarius A; Pfirrmann M; Kohlmann A; Grossmann V; Meggendorfer M; Horny HP; Valent P; Jawhar M; Teichmann M; Metzgeroth G; Erben P; Ernst T; Hochhaus A; Haferlach T; Hofmann WK; Cross NC; Reiter A
    Blood; 2013 Oct; 122(14):2460-6. PubMed ID: 23958953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
    Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
    J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
    Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
    Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
    Jawhar M; Schwaab J; Schnittger S; Meggendorfer M; Pfirrmann M; Sotlar K; Horny HP; Metzgeroth G; Kluger S; Naumann N; Haferlach C; Haferlach T; Valent P; Hofmann WK; Fabarius A; Cross NC; Reiter A
    Leukemia; 2016 Jan; 30(1):136-43. PubMed ID: 26464169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic mastocytosis mimicking blastic plasmacytoid dendritic cell neoplasm: a case report.
    Zhang X; Han J; Zhu N; Ji Y; Hou Y
    Diagn Pathol; 2023 Feb; 18(1):17. PubMed ID: 36759849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of optical genome mapping for detecting chromosomal translocation in clinical cytogenetics.
    Dai P; Zhu X; Pei Y; Chen P; Li J; Gao Z; Liang Y; Kong X
    Mol Genet Genomic Med; 2022 Jun; 10(6):e1936. PubMed ID: 35384386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.